Should US Taxpayers Have Payed For The AMBASSADOR Trial? A poll.
The AMBASSADOR trial has been published in the New England Journal of Medicine, and presented at ESMO 2024. This was a collaborative ALLIANCE trial testing 1 year of adjuvant pembrolizumab in localized bladder cancer after radical surgery. The randomized trial was conducted exclusively in the US, and demonstrated a disease-free survival benefit (DFS), but no overall benefit for now.
The trial was funded by the National Cancer Institute. Below is the expected compound annual growth rate (CAGR) from the product KEYTRUDA (pembrolizumab), according to Merck.
Now a simple poll for the drugdevletter.com readers! Please vote below and let us know what you think in the comments !
As long as profits are skyrocketing, pharma should pay for these studies, and all protocols and supplements should be open accessible for rechecking the results. Vice versa, if the studies are to be paid by taxpayers, the price of the drug should be set by them, too…
Has anyone studied what percentage of cancer patients simply decline chemotherapy? I am wondering if it is similar to the vaccines, where increasing numbers of people see no benefit to themselves. Thank you.